Acetazolamide Sodium: A Potential Treatment for Normal Pressure Hydrocephalus

What is Acetazolamide?

Acetazolamide Sodium, also known by its scientific name (5-ACETAMIDO-1,3,4-THIADIAZOL-2-YL)SULFONYLAZANIDE SODIUM, is a medication being studied for its potential in treating Normal Pressure Hydrocephalus (NPH)1. It belongs to a class of drugs called carbonic anhydrase inhibitors, which affect certain processes in the body related to fluid balance.

Normal Pressure Hydrocephalus: The Target Condition

Normal Pressure Hydrocephalus is a condition where excess cerebrospinal fluid accumulates in the brain's ventricles, causing various symptoms. It typically affects older adults and can lead to problems with walking, thinking, and bladder control1.

Research Objectives

A clinical trial is being conducted to investigate the effects of Acetazolamide in patients with NPH. The main goals of this research are:

1. To examine how Acetazolamide affects walking ability in NPH patients1.
2. To assess changes in patients' symptoms and quality of life over time1.
3. To observe changes in brain imaging (MRI) parameters, focusing on:
   • White matter changes around the ventricles
   • Blood flow in the brain
   • Overall brain structure1
4. To evaluate the safety and side effects of Acetazolamide in NPH patients1.
5. To measure changes in certain biological markers in blood and cerebrospinal fluid after treatment1.

Potential Benefits of Acetazolamide

While the full effects are still being studied, researchers hope that Acetazolamide may help improve symptoms of NPH, particularly:

• Walking ability: The study will closely monitor changes in gait (walking pattern) as a primary measure of the drug's effectiveness1.
• Quality of life: Researchers will assess whether the medication leads to overall improvements in patients' daily lives and well-being1.
• Brain health: The study will look at whether Acetazolamide can positively affect brain structure and function, as seen on MRI scans1.

Eligibility Criteria for the Study

To participate in this research, patients must meet specific criteria, including:

• Having a diagnosis of idiopathic (unknown cause) Normal Pressure Hydrocephalus1.
• Being between 50 and 82 years old1.
• Having adequate cognitive function (as measured by specific tests)1.
• Showing certain brain imaging features on MRI consistent with NPH1.

There are also several factors that would exclude a person from participating, such as certain medical conditions, medications, or inability to perform required tasks1.

What the Study Will Measure

To determine if Acetazolamide is effective, the researchers will look at several factors:

• Changes in walking ability, including:
  • Time and steps needed to walk 10 meters
  • Performance on a "timed up-and-go" test
  • Ability to walk backwards for 3 meters1
• Quality of life assessments using questionnaires1.
• Changes in brain imaging results1.
• Overall changes in motor skills, thinking ability, and bladder control1.
• Levels of certain proteins in blood and cerebrospinal fluid that may indicate brain health1.

Safety Considerations

As with any medication, there are important safety considerations for using Acetazolamide:

• The study excludes people with allergies to Acetazolamide or similar drugs1.
• Certain medical conditions, such as kidney problems, liver issues, or heart failure, may prevent participation1.
• The medication may interact with other drugs, so some medications are not allowed during the study1.
• Pregnant women or those who may become pregnant are excluded for safety reasons1.

It's important to note that this is an investigational use of Acetazolamide for NPH. The study aims to carefully monitor its effects and safety in this specific patient group1.